Up to 40% of LGL leukemia patients harbor a STAT3 mutation[9], and therefore represent a population in need of novel therapies that can block mutant STAT3 associated cell survival. This evidence concerns the gene STAT3 and T-cell large granular lymphocyte leukemia.